Celcuity Inc (NAS:CELC)

$ 16.395 0.465 (2.92%) Market Cap: 575.48 Mil Enterprise Value: 418.73 Mil PE Ratio: 0 PB Ratio: 3.77 GF Score: 29/100

Q1 2024 Celcuity Inc Earnings Call Transcript
May 15, 2024

$17.23 (+2.01%)

Earnings
Q4 2023 Celcuity Inc Earnings Call Transcript
Mar 27, 2024

$18.16 (+3.65%)

Earnings
Q3 2023 Celcuity Inc Earnings Call Transcript
Nov 13, 2023

$10.89 (+1.11%)

Earnings
Celcuity Inc Science Day (Virtual) Transcript
Sep 21, 2023
Q2 2023 Celcuity Inc Earnings Call Transcript
Aug 10, 2023

$10 (+0.10%)

Earnings
Q1 2023 Celcuity Inc Earnings Call Transcript
May 15, 2023

$9.58 (-0.73%)

Earnings
Celcuity Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 19, 2023
Q4 2022 Celcuity Inc Earnings Call Transcript
Mar 23, 2023

$10.06 (+0.50%)

Earnings
Q3 2022 Celcuity Inc Earnings Call Transcript
Nov 10, 2022

$10 (-0.50%)

Earnings
Q2 2022 Celcuity Inc Earnings Call Transcript
Aug 11, 2022

$10.64 (+1.33%)

Earnings
Q1 2022 Celcuity Inc Earnings Call Transcript
May 16, 2022

$5.66 (+5.79%)

Earnings
Celcuity Inc at Canaccord Genuity Horizons in Oncology Conference (Virtual) Transcript
Apr 14, 2022
Celcuity Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 12, 2022
Q4 2021 Celcuity Inc Earnings Call Transcript
Mar 23, 2022

$8.04 (-1.83%)

Earnings
Q3 2021 Celcuity Inc Earnings Call Transcript
Nov 08, 2021

$18.85 (-0.48%)

Earnings
Q2 2021 Celcuity Inc Earnings Call Transcript
Aug 09, 2021

$20.57 (-1.34%)

Earnings
Q1 2021 Celcuity Inc Earnings Call Transcript
May 10, 2021

$25.17 (-7.26%)

Earnings
Celcuity Inc Announces Worldwide Licensing Agreement with Pfizer - Corporate Call Transcript
Apr 08, 2021
Q4 2020 Celcuity Inc Earnings Call Transcript
Feb 16, 2021

$16.46 (-0.66%)

Earnings
Q3 2020 Celcuity Inc Earnings Call Transcript
Nov 09, 2020

$5.8 (+1.93%)

Earnings
Q2 2020 Celcuity Inc Earnings Call Transcript
Aug 10, 2020

$6.14 (-0.81%)

Earnings
Q1 2020 Celcuity Inc Earnings Call Transcript
May 07, 2020

$5.51 (-5.00%)

Earnings
Q4 2019 Celcuity Inc Earnings Call Transcript
Mar 12, 2020

$6.73 (-5.48%)

Earnings
Q3 2019 Celcuity Inc Earnings Call Transcript
Nov 07, 2019

$14.04 (-0.43%)

Earnings
Q2 2019 Celcuity Inc Earnings Call Transcript
Aug 08, 2019

$19.8 (-0.85%)

Earnings
Q1 2019 Celcuity Inc Earnings Call Transcript
May 07, 2019

$21.8 (-1.80%)

Earnings
Q4 2018 Celcuity Inc Earnings Call Transcript
Feb 26, 2019

$23.31 (-3.08%)

Earnings

Celcuity Inc Science Day (Virtual) Transcript

Sep 21, 2023 / 02:00PM GMT

Release Date Price: $9.94 (-0.40%)

Transcript

Brian F. Sullivan

Celcuity Inc. - Co-Founder, Chairman & CEO

Well, good morning, everyone. Thank you for joining us today. I'm Brian Sullivan, CEO and Co-Founder of Celcuity. We're excited to have the opportunity today to discuss our plan to develop gedatolisib to unlock the potential of treating cancers involving PI3K/mTOR signaling.

Joining me today from Celcuity are Lance Laing, CSO and my fellow Co-Founder, and Igor Gorbatchevsky, our Chief Medical Officer. I'm also especially pleased to introduce you to Dr. Sara Hurvitz and Dr. Karim Fizazi. Dr. Hurvitz is Professor of Medicine, Head of the Division of Hematology and Oncology and Senior Vice President of University of Washington, Fred Hutchinson Cancer Center. Her practice specialty is breast cancer and she served in leadership capacities for many of the major breast cancer studies conducted over the past decade.

Dr. Fizazi is Professor of Medicine and Head of the Genitourinary Group at Institute Gustav Roussy at the University of Paris-Saclay. He also serves as President of the Urogenital Study Group, France's National

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.